Potassium Bicarbonate
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Potassium Bicarbonate: From Potassium Supplementation to Gastroduodenitis
One-Sentence Summary
Potassium Bicarbonate is an electrolyte/alkalizing agent conventionally used for potassium supplementation, and it is not currently marketed in Taiwan. The TxGNN model predicts it may be effective for Gastroduodenitis, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a pure knowledge-graph inference with no direct evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No approved indication on record (drug not marketed in Taiwan) |
| Predicted New Indication | Gastroduodenitis |
| TxGNN Prediction Score | 99.72% |
| Evidence Level | L5 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, Potassium Bicarbonate functions as an alkalizing agent and electrolyte supplement, and is commonly used for potassium replacement therapy.
The proposed link to gastroduodenitis is mechanistically speculative: as an alkalizing salt, potassium bicarbonate could theoretically neutralize gastric acid in a manner analogous to sodium bicarbonate’s antacid effect, which might relieve symptoms associated with gastroduodenal inflammation. However, this is an indirect pharmacological analogy rather than an established mechanism — there is no evidence confirming anti-inflammatory or mucosal-protective activity specific to this indication.
Because the drug has no recorded original indication, is not currently marketed, and the TxGNN score derives purely from graph-structural inference (rank 7528), the biological plausibility of this prediction cannot be independently corroborated at this time.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
US Market Information
No licenses currently on file — Potassium Bicarbonate is not marketed in Taiwan, and no dosage forms or approved indications are available for reference.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests solely on a TxGNN structural score with no supporting clinical trials, literature, or mechanistic data (L5), and the drug is not currently marketed in Taiwan, so there is no regulatory or safety baseline to build on.
To proceed, the following is needed:
- TFDA package insert warnings/contraindications (currently blocking — DG001)
- Confirmed mechanism of action from DrugBank (DG002)
- At least preclinical or case-level evidence connecting potassium bicarbonate to gastroduodenitis
- Clarification of original approved indication(s) and any historical marketing history, if applicable
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.